Navigation Links
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Date:7/19/2009

ownload any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies, and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer.

The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) for lupus. Albuferon has now completed Phase 3 development, and the submission of global marketing applications is expected in fall 2009. BENLYSTA successfully met its primary endpoint in the first of two Phase 3 trials in systemic lupus erythematosus; results of the second BENLYSTA Phase 3 trial are expected in November 2009. Also in late-stage development is raxibacumab (ABthrax(TM)) for the treatment of inhalation anthrax (Biologics License Application currently pending with the U.S. Food and Drug Administration). In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development in patients with coronary heart disease, and Syncria(R) (albiglutide), currently in Phase 3 development in patients with type 2 diabetes.

For more information about HGS, please
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Seres Health, a clinical-stage therapeutics company ... human microbiome, announced today that Dr. David ... and Chief Scientific Officer, will be presenting at ... Chemotherapy (ICAAC). The presentation will highlight the scientific ... of bacterial spores derived from the human microbiome, ...
(Date:8/28/2014)... 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... clearance for and commercializing its CE Marked APPY ... identifying children, adolescent, and young adult patients in the ... today announced it will present at three upcoming investor ... Global Investment Conference being held in New ...
(Date:8/28/2014)... PLYMOUTH MEETING, Pa. , Aug. 28, 2014 ... surgical community, patients, and media, both for the ... to patient safety. The quick deployment of surgical ... new technology are prompting facilities to evaluate their ... for the entire surgical team.    ...
Breaking Medicine Technology:Seres Health to Present Clinical Findings at ICAAC 2014 Conference 2Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... Delcath Systems, Inc. (Nasdaq: DCTH ) today ... of Directors. Dr. Contag is a proven corporate executive with ... , (LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ... Cobalt Technologies, Inc. in 2006 and served as CEO. Prior ...
... & Alzheimer,s Disease , , ... today announced that its researchers have uncovered a new ... a potential target for developing novel therapeutics for intervention ... Institute,s Pancham Bakshi, Ph.D., is detailed in the ...
Cached Medicine Technology:Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 2Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease 3
(Date:8/28/2014)... 28, 2014 Testimony began this ... a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving ... LLP reports. Court documents pending in the U.S. ... that the case was filed on behalf of ... surgeries, allegedly due to vaginal mesh complications associated ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 The Governor ... Microcredit Summit at a press conference; this event ... with the Ministry of Economy through the National Microenterprise ... from September 2nd to the 5th at the Convention ... , “It is a great responsibility for Yucatan to ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , is ... by walking 5,000 miles in a single year without ever ... thousands of individual stories of TrekDesk treadmill desk users across ... than the others. , Kirklyn has launched a website that ... range of 54,823 steps (presumably on an off day) to ...
(Date:8/28/2014)... August 28, 2014 Bank lending to the ... year, down by 0.13% in real terms, and continuing to ... new study by UHY, the international accountancy network. , UHY ... businesses in particular, the credit crunch lingers on. , UHY ... the last year have been wiped out by inflation. Over ...
(Date:8/28/2014)... of sleep not only puts teens at risk for poor ... researchers warn. The study authors analyzed data collected from ... 21. Nearly one-fifth of them got less than six hours ... this group was 20 percent more likely to be obese ... hours of sleep per night at age 16, the investigators ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 2Health News:Governor of the State of Yucatan presents the 17th Microcredit Summit 3Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 2Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 3Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 4Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 5Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 6Health News:UHY Study Shows Bank Lending In USA Falling Behind G7 Peers 7Health News:Less Sleep in Teen Years Tied to More Pounds at 21 2
... new study, a serious form of cancer that arises in ... normally serve as ‘scouts’ for the immune system. ... virus (EBV), which is usually kept under check by the ... control is lost and the transplanted organ may be rejected. ...
... characterized by pain and tenderness in the jaw muscles ... ,TMD is a problem for millions of Americans whose ... open-joint surgery. Whole system naturopathic care as a treatment ... of a new study involving 160 women in the ...
... a research conducted to study the link between work-related ... real or threatened violence at workplace run a major ... showed that the magnitude of the risk was in ... ,The findings of the study have been published ...
... of just a few puffs of cigarette that is capable ... that the amount of nicotine present in a single puff ... receptors and 3 puffs can occupy nearly 70% of these ... the receptors are filled up. But this feeling of satisfaction ...
... has now risen to 19 from 17. The official ... encephalitis was spreading rapidly.// ,Health officials in ... infections had emerged since July 13. Encephalitis causes the ... left untreated can be fatal. In China, health authorities ...
... The calories that contribute to ill health are loaded in ... consequentially off the lives of many // , who are ... with, the ideal thing would be to ensure the promotional ... that people are dished out the right information about healthy ...
Cached Medicine News:Health News:Deficient 'Scout Cells' Causes Cancer in Transplant Patients 2Health News:Deficient 'Scout Cells' Causes Cancer in Transplant Patients 3Health News:Naturopathic Care Proves Beneficial for TMD Pain 2Health News:Work-Related Violence Increases Risk Of Depression 2Health News:Imaging study affords renewed thrust on smoking cessation treatments 2Health News:Imaging study affords renewed thrust on smoking cessation treatments 3
Lyphochek Urine Bone Markers Control is a bilevel human urine based control designed to monitor tests for urinary markers of osteoporosis management and bone resorption....
... Control is designed to ... significant range of those ... during fertility or pregnancy ... hCG-Beta Subunit levels allow ...
... provides the clinical laboratory with the ... for monitoring immunoassay and therapeutic drug ... separate controls. Made from human serum ... suitable for most methods and is ...
Lyphochek Immunology Plus Control is an assayed control for monitoring chemistry procedures that test for autoimmune, anemic, malignant, hepatic and nephrotic-disease states. Available in two levels....
Medicine Products: